Common Contracts
4 similar Share Purchase Agreement contracts by Odyssey Therapeutics, Inc.
SHARE PURCHASE AGREEMENT AMONG ODYSSEY THERAPEUTICS, INC., RAHKO LIMITED, BALDERTON CAPITAL GENERAL PARTNER VI S.L.P AND ROBERT IAN HOROBIN AND MIRIAM CHA, AS SELLERS’ REPRESENTATIVES DATED AS OF OCTOBER 6, 2021Share Purchase Agreement • April 17th, 2026 • Odyssey Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Share Purchase Agreement (this “Agreement”), dated as of October 6, 2021, is made by and among ODYSSEY THERAPEUTICS, INC., a Delaware corporation (“Buyer”), RAHKO LIMITED, a private limited company incorporated in England & Wales (registered number 11609778) (the “Company”), BALDERTON CAPITAL VI S.L.P, acting by its general partner Balderton Capital General Partner VI S.à.r.l, of [***] (the “Seller”), and ROBERT IAN HOROBIN of [***] and MIRIAM CHA of [***], solely in their capacity as the Seller’s Representatives (as defined below).
SHARE PURCHASE AGREEMENT AMONG ODYSSEY THERAPEUTICS, INC., RAHKO LIMITED, SELLERS, AND ROBERT IAN HOROBIN AND MIRIAM CHA, AS SELLERS’ REPRESENTATIVES DATED AS OF OCTOBER 6, 2021Share Purchase Agreement • April 17th, 2026 • Odyssey Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Share Purchase Agreement (this “Agreement”), dated as of October 6, 2021, is made by and among ODYSSEY THERAPEUTICS, INC., a Delaware corporation (“Buyer”), RAHKO LIMITED, a private limited company incorporated in England & Wales (registered number 11609778) (the “Company”), each of the shareholders listed in Part 1 and Part 2 of Schedule I (the “Sellers”), and ROBERT IAN HOROBIN of [***] and MIRIAM CHA of [***], solely in their capacity as the Sellers’ Representatives (as defined below).
SHARE PURCHASE AGREEMENT AMONG ODYSSEY THERAPEUTICS, INC., RAHKO LIMITED, BALDERTON CAPITAL GENERAL PARTNER VI S.L.P AND ROBERT IAN HOROBIN AND MIRIAM CHA, AS SELLERS’ REPRESENTATIVES DATED AS OF OCTOBER 6, 2021Share Purchase Agreement • February 6th, 2026 • Odyssey Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Share Purchase Agreement (this “Agreement”), dated as of October 6, 2021, is made by and among ODYSSEY THERAPEUTICS, INC., a Delaware corporation (“Buyer”), RAHKO LIMITED, a private limited company incorporated in England & Wales (registered number 11609778) (the “Company”), BALDERTON CAPITAL VI S.L.P, acting by its general partner Balderton Capital General Partner VI S.à.r.l, of [***] (the “Seller”), and ROBERT IAN HOROBIN of [***] and MIRIAM CHA of [***], solely in their capacity as the Seller’s Representatives (as defined below).
SHARE PURCHASE AGREEMENT AMONG ODYSSEY THERAPEUTICS, INC., RAHKO LIMITED, SELLERS, AND ROBERT IAN HOROBIN AND MIRIAM CHA, AS SELLERS’ REPRESENTATIVES DATED AS OF OCTOBER 6, 2021Share Purchase Agreement • February 6th, 2026 • Odyssey Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Share Purchase Agreement (this “Agreement”), dated as of October 6, 2021, is made by and among ODYSSEY THERAPEUTICS, INC., a Delaware corporation (“Buyer”), RAHKO LIMITED, a private limited company incorporated in England & Wales (registered number 11609778) (the “Company”), each of the shareholders listed in Part 1 and Part 2 of Schedule I (the “Sellers”), and ROBERT IAN HOROBIN of [***] and MIRIAM CHA of [***], solely in their capacity as the Sellers’ Representatives (as defined below).